UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Sep

    17

    BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

    Sep

    17

    BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

    Sep

    10

    Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

    Sep

    10

    Gen Z and Millennial Patients Find “Rheum for Improvement” in Disease Management

    Sep

    08

    The profound impact on the lives of people living with thymidine kinase 2 deficiency (TK2d)

    Sep

    03

    The Sniff That Saves: Honoring Service Dogs This Awareness Month